| US 7,531,552 B2 | ||
| Indole, azaindole and related heterocyclic pyrrolidine derivatives | ||
| John F. Kadow, Wallingford, Conn. (US); Qiufen May Xue, Newbury Park, Calif. (US); Tao Wang, Farmington, Conn. (US); Zhongxing Zhang, Madison, Conn. (US); and Nicholas A. Meanwell, East Hampton, Conn. (US) | ||
| Assigned to Bristol-Myers Squibb Company, Princeton, N.J. (US) | ||
| Filed on Dec. 20, 2007, as Appl. No. 11/960,885. | ||
| Application 11/960885 is a continuation of application No. 11/511123, filed on Aug. 28, 2006, abandoned. | ||
| Prior Publication US 2008/0096912 A1, Apr. 24, 2008 | ||
| Int. Cl. A61K 31/437 (2006.01); C07D 471/04 (2006.01) | ||
| U.S. Cl. 514—300 [546/113; 514/414; 548/467] | 2 Claims |
1. A compound of Formula I, including pharmaceutically acceptable salts thereof
 Z is
 A is selected from the group consisting of phenyl and D; wherein D is selected from the group consisting of pyridinyl, furanyl
and thienyl; wherein phenyl and D are independently optionally substituted with one or two of the same or different amino
or halogen;
W is selected from the group consisting of
 R1 is hydrogen; and
Q is a member selected from the groups (A) and (B) consisting of
  R3 and R4 are selected from the group consisting of hydrogen, halogen, methoxy, cyano, COOR8, C(O)NHCH3, C(O)NHheteroaryl and heteroaryl; and R6 does not exist;
and - - represents a carbon-carbon bond in (A) and (B);
R7 is (CH2)nR44 wherein n is 0-6;
R8 is selected from the group consisting of hydrogen and (C1-6)alkyl;
R9 is selected from the group consisting of hydrogen and methyl;
R44 is selected from the group consisting of H, (C1-6)alkyl, CO(C1-6)alkyl, C(O)— phenyl and —CONRaRb;
Ra and Rb are each independently H, (C1-6)alkyl or phenyl.
|